Cough - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 96
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C4D3EBD6A43EN
Leaflet:

Download PDF Leaflet

Cough - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Cough - Pipeline Review, H2 2016’, provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Cough
  • The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
  • The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cough
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cough
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cough Overview
Therapeutics Development
Pipeline Products for Cough - Overview
Pipeline Products for Cough - Comparative Analysis
Cough - Therapeutics under Development by Companies
Cough - Therapeutics under Investigation by Universities/Institutes
Cough - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cough - Products under Development by Companies
Cough - Products under Investigation by Universities/Institutes
Cough - Companies Involved in Therapeutics Development
Afferent Pharmaceuticals, Inc.
Alitair Pharmaceuticals, Inc.
Alveonix AG
AstraZeneca Plc
AusBio Ltd
Charleston Laboratories, Inc.
Conrig Pharma ApS
Daewoong Pharmaceutical Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GW Pharmaceuticals Plc
Hyundai Pharmaceutical Co., Ltd.
Johnson & Johnson
NeRRe Therapeutics Ltd
Orbis Biosciences Inc
Patara Pharma, Inc.
Pila Pharma AB
Vernalis Plc
Cough - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ax-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzonatate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLAT-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
codeine + guaifenesin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRC-17536 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2339345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin + hydrocodone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39729209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lesogaberan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levodropropizine CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-990 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1226 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cough - Dormant Projects
Cough - Discontinued Products
Cough - Product Development Milestones
Featured News & Press Releases
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Apr 29, 2014: Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cough, H2 2016
Number of Products under Development for Cough - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016
Cough - Pipeline by Alveonix AG, H2 2016
Cough - Pipeline by AstraZeneca Plc, H2 2016
Cough - Pipeline by AusBio Ltd, H2 2016
Cough - Pipeline by Charleston Laboratories, Inc., H2 2016
Cough - Pipeline by Conrig Pharma ApS, H2 2016
Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Cough - Pipeline by GlaxoSmithKline Plc, H2 2016
Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016
Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Cough - Pipeline by Johnson & Johnson, H2 2016
Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016
Cough - Pipeline by Orbis Biosciences Inc, H2 2016
Cough - Pipeline by Patara Pharma, Inc., H2 2016
Cough - Pipeline by Pila Pharma AB, H2 2016
Cough - Pipeline by Vernalis Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cough - Dormant Projects, H2 2016
Cough - Dormant Projects (Contd.1), H2 2016
Cough - Dormant Projects (Contd.2), H2 2016
Cough - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Cough, H2 2016
Number of Products under Development for Cough - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Afferent Pharmaceuticals, Inc.
Alitair Pharmaceuticals, Inc.
Alveonix AG
AstraZeneca Plc
AusBio Ltd
Charleston Laboratories, Inc.
Conrig Pharma ApS
Daewoong Pharmaceutical Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GW Pharmaceuticals Plc
Hyundai Pharmaceutical Co., Ltd.
Johnson & Johnson
NeRRe Therapeutics Ltd
Orbis Biosciences Inc
Patara Pharma, Inc.
Pila Pharma AB
Vernalis Plc
Skip to top


Ask Your Question

Cough - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: